|Headquarters||Hyderabad, Telengana, India|
|P.V.Ramprasad Reddy, K. Nithyananda Reddy, Dr. M. Sivakumaran, Mr. Madanmohan Reddy, Mr. Govind, Mr. Arvind Vasudeva,|
|Products||Formulation, Active Pharmaceutical Ingredient, Organic Intermediates|
Aurobindo Pharma Limited is a pharmaceutical manufacturing company headquartered in HITEC City, Hyderabad, India. The company manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company’s area of activity includes six major therapeutic/product areas: antibiotics, anti-retrovirals, cardiovascular products, central nervous system products, gastroenterologicals, and anti-allergics. The company markets these products in over 125 countries. Its marketing partners include AstraZeneca and Pfizer.
The company commenced operations in 1988-89 with a single unit manufacturing Semi-Synthetic Penicillin (SSP) at Pondicherry. Aurobindo Pharma became a public company in 1992 and listed its shares in the Indian stock exchanges in 1995. In addition to being the market leader in Semi-Synthetic Penicillins, it has a presence in key therapeutic segments such as neurosciences, cardiovascular, anti-retrovirals, anti-diabetics, gastroenterology and cephalosporins, among others.
Aurobindo Pharma features among the top 10 companies in India in terms of consolidated revenues. Aurobindo exports to over 125 countries across the globe with more than 70% of its revenues derived out of international operations.
- "Aurobindo Pharma signs supply pact with AstraZeneca", Economic Times, September 6, 2010
- "Pfizer, Astra deals to drive Aurobindo Pharma’s growth", Economic Times, November 5, 2010
- "Aurobindo Buys Actavis' European Operations". News: Industry Watch. Gen. Eng. Biotechnol. News (paper) 34 (4). 15 February 2014. p. 10.
- "Aurobindo To Buyout Actavis' EU Ops". Bloomberg TV India. Retrieved 20 January 2014.